Reuters logo
BRIEF-Sucampo Pharmaceuticals announces FDA acceptance of sNDA for AMITIZA
September 28, 2017 / 9:39 PM / 22 days ago

BRIEF-Sucampo Pharmaceuticals announces FDA acceptance of sNDA for AMITIZA

Sept 28 (Reuters) - Sucampo Pharmaceuticals Inc

* Sucampo Pharmaceuticals announces FDA acceptance of sNDA for amitiza in children with pediatric functional constipation, with priority review designation

* Sucampo Pharmaceuticals Inc - ‍FDA has assigned a user fee goal date of January 28, 2018.​

* Sucampo Pharmaceuticals Inc - ‍filing has received priority review designation from FDA​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below